The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study

Selvi Y., Atli A., Aydin A., Besiroglu L., Ozdemir P., Ozdemir O.

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.26, no.1, pp.51-57, 2011 (SCI-Expanded) identifier identifier identifier


Objective To investigate the comparative efficacy of aripiprazole and risperidone as augmenting agents in the treatment of obsessive-compulsive disorder (OCD) patients who did not show a >= 35% decrease in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) after 12-week monotherapy with selective serotonin reuptake inhibitors (SSRIs).